Biochemical and Biophysical Research Communications
Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells
Section snippets
Materials and methods
Cell culture. Human venous endothelial cells (HUVEC) were isolated from umbilical cords and cultured according to standard procedures. The endothelial phenotype was confirmed using phase-contrast microscopy and staining for the endothelial-specific von Willebrand factor. Confluent cell layers were exposed to rosuvastatin concentrations ranging from 10−8 to 10−5 mol/l for 8 or 12 h. In some experiments, the media were supplemented with mevalonic acid (MEV, 10−4 mol/l), geranylgeranylpyrophosphate
Effects of rosuvastatin on cell viability of HUVEC
As presented in Fig. 1, after 12 h exposure to rosuvastatin (10−8–10−5 mol/l) viability of human endothelial cells was only marginally affected. As this was not concentration-related it may reflect variability in the assay. Addition of the isoprenoid intermediates mevalonic acid, GGPP or FPP in the presence of the statin did not change cell viability.
Rosuvastatin increases eNOS mRNA and protein expression in a concentration-dependent manner
Treatment of endothelial cells with rosuvastatin for 8 h increased eNOS mRNA and protein expression in a concentration-dependent manner. As shown in
Discussion
The presented data show that rosuvastatin, which is a hydrophilic statin, has no relevant effect on the viability of human endothelial cells. This is in accordance with a previously published study by Kaneta et al. [19]. The authors were able to show that the hydrophilic pravastatin had no effect on cell viability after a 24-h incubation period in murine endothelial cells. As hydrophobic statins can enter endothelial cells by penetrating the lipid bilayers of the cell membranes, they are able
Acknowledgments
The authors thank the Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ernst-Moritz-Arndt-Universität, Greifswald, Germany, for the generous supply of human umbilical cords. The excellent technical assistance of R. Dressler and M. Wendt is gratefully acknowledged. We are grateful to Dr. J. Sonnemann, Peter Holtz Research Centre of Pharmacology and Experimental Therapeutics, for his initial help with the Alamar Blue assay. This research was supported by a grant from AstraZeneca to
References (24)
- et al.
Statins do more than just lower cholesterol
Lancet
(1996) - et al.
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
J. Am. Coll. Cardiol.
(1998) - et al.
Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect
FEBS Lett.
(2001) Beyond lipid lowering: the role of statins in vascular protection
Int. J. Cardiol.
(2002)- et al.
Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family
Biochem. Biophys. Res. Commun.
(2000) - et al.
Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1
Biochem. Biophys. Res. Commun.
(2004) - et al.
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice
Brain Res.
(2002) - et al.
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method
Methods
(2001) - et al.
All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells
Atherosclerosis
(2003) - et al.
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
J. Biol. Chem.
(1998)